Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 7, 2014; 20(41): 15358-15366
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15358
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15358
Table 1 Demographics of the study population n
Characteristics | CD (n =292) | UC (n = 206) | IC (n = 2) |
Age (yr, mean ± SD) | 41.94 ± 16.3 | 43.2 ± 16.6 | 46.5 ± 37.5 |
Sex (Male/Female) | 110/182 | 85/121 | 0/2 |
Race | |||
African American | 66 (22%) | 37 (18%) | 0 (0%) |
Asian | 3 (1%) | 2 (1%) | 0 (0%) |
Native American | 2 (0.7%) | 1 (0.5%) | 0 (0%) |
White | 200 (68%) | 148 (72%) | 2 (100%) |
Ethnicity | |||
Hispanic | 14 (4.8%) | 16 (8%) | 0 (0%) |
Not hispanic | 278 (95%) | 190 (92%) | 2 (100%) |
Immunosuppressants | 187 (64%) | 109 (53%) | 2 (100%) |
IBD disease duration | |||
(mo, mean ± SD) | 154 ± 138 | 107 ± 106 | 4 ± 4 |
Table 2 Prevalence of hepatitis B virus markers in subjects who have serology data available n (%)
Disease Type | HBsAg | Anti-HBc Ab |
Crohn’s disease (n = 143) | 4 (2.8) | 6 (4.2) |
Ulcerative colitis (n = 76) | 0 (0) | 1 (1.3) |
Indeterminate colitis (n = 1) | 0 (0) | 0 (0) |
Total (n = 220) | 4 (1.8) | 7 (3.2) |
Table 3 Characteristics of the 7 hepatitis B virus - positive patients
Patients | Age (yr) | Sex | Ethnicity | IBD | Immunosupression | Serology | Viral Load (copies/mL) | HBV states |
1 | 54 | Male | White | CD | Adalimumab | HBsAg+ | 135039 | Chronic infection |
Azathioprine | Anti-HBs Ab- | |||||||
HBeAg+ | ||||||||
Anti-HBe Ab- | ||||||||
Anti-HBc Ab+ | ||||||||
2 | 56 | Female | African american | CD | - | HBsAg+ | 244 | Chronic infection |
Anti-HBs Ab- | ||||||||
Anti-HBc Ab+ | ||||||||
HBeAg- | ||||||||
3 | 56 | Female | White | CD | - | HBsAg+ | 121 | Chronic infection |
Anti-HBs Ab- | ||||||||
Anti-HBc Ab+ | ||||||||
HBeAg- | ||||||||
4 | 61 | Male | African american | CD | - | HBsAg+ | 1000000 | Chronic infection |
Anti-HBs Ab- | ||||||||
HBeAg+ | ||||||||
Anti-HBe Ab- | ||||||||
Anti-HBc Ab+ | ||||||||
5 | 54 | Female | African american | CD | Adalimumab | HBsAg- | < 10 | Past infection, |
Anti-HBs Ab+ | Naturally immune | |||||||
Anti-HBc Ab+ | ||||||||
6 | 62 | Female | African american | UC | - | HBsAg- | - | Past infection, |
Anti-HBs Ab+ | Naturally immune | |||||||
Anti-HBc Ab+ | ||||||||
7 | 64 | Female | African american | CD | Prednisolone | HBsAg- | - | Past infection, |
Anti-HBs Ab+ | Naturally immune | |||||||
Anti-HBc Ab+ |
Table 4 Prevalence of hepatitis B virus in our inflammatory bowel disease study vs in European studies
Loras 2009 (study 1) | Chevaux 2010 (study 2) | Our IBD study | Study 1 vs our study(P value) | Study 2 vs our study(P value) | |
Chronic HBV (HBsAg) | 0.7% | 0.95% | 1.8% | 0.070 | 0.159 |
Exposure to HBV (Anti-HBc Ab) | 7.5% | 2.50% | 3.2% | 0.006 | 0.313 |
- Citation: Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(41): 15358-15366
- URL: https://www.wjgnet.com/1007-9327/full/v20/i41/15358.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i41.15358